

Ref: MHL/Sec&Legal/2019/57

Date: November 12, 2019

To,

**Head, Listing Compliance Department
BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

**Head, Listing Compliance Department
National Stock Exchange of India Limited**
Exchange Plaza,
Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai – 400051

Scrip Code: **542650**

Scrip Symbol: **METROPOLIS**

Sub: Revised Press Release for H1FY20 Results

Ref: Intimation dated November 11, 2019 vide letter MHL/Sec&Legal/2019/53

Dear Sir/Madam,


With reference to the above letter on the captioned subject, we would like to inform you that the Press release has been revised.

Requested to consider this Press release as attached.

Kindly take the same on the records.

Yours faithfully

For Metropolis Healthcare Limited


Ameera Sushil Shah
Managing Director
DIN: 00208095



METROPOLIS
The Pathology Specialist

INNER HEALTH REVEALED

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: U73100MH2000PLC192798. Tel: +91-22-3399 3939 / 6650 5555.

Email: support@metropolisindia.com | Website: www.metropolisindia.com

Central Laboratory: 4th Floor, Commercial Building-IA, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare announces H1FY20 and Q2FY20 results

- Q2FY20 Revenue Growth at **15.6%** driven by Volume Growth and Organic Expansion
- H1FY20 EBDITA Growth at **21.3%** on Y-o-Y basis
- Q2FY20 PAT @ INR 43 crore (**43.7% growth**)

Monday, November 11, 2019, Mumbai: Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its un-audited consolidated financial results today for the quarter ended September 30, 2019.

| Revenue | Patient Visits | No of Tests |
|--|--|--|
| Rs. 427 Cr +15.6% YoY for H1 Rs. 223 Cr +15.6% YoY for Q2 | 4.92 Mn +16.3% YoY for H1 2.66 Mn +15.7% YoY for Q2 | 9.51 Mn +20.3% YoY for H1 5.17 Mn +20.1% YoY for Q2 |

Key Highlights H1FY20

- Our network as of H1 FY20 consists of **124 laboratories** and **2712 patient service centers**.
- Overall revenue from **B2C** stood at **44.4% in H1FY20** as compared to 43.6% in H1FY19
- In Focused Cities B2C revenues have grown to **Rs. 131 crs** registering a growth of **17% on YoY basis**. B2C Share in Focused Cities was higher at **56% as compared to 52% in H1FY19**
- Acquisition of **4 front end labs in Surat** has helped us expand our market share in this focus city.
- Our Delhi Regional Reference Lab has been relocated and expanded to 15,000 sq ft from 8,000 sq ft. earlier which allows us for test menu expansion, faster turn around and
- A total of **14 new tests** (in areas of Genomics, Onco-pathology, new-born screening and transplant pathology) have been validated and added to the test menu in H1FY20 thus expanding our capabilities to do more specialized tests.
- A few technology and digital initiatives have gone live in H1FY20 that enables better control, data security, business continuity, business revenue generation capabilities, improved operational efficiency, efficiencies in productivity and an improved customer experience.

I am happy to present our quarterly and half yearly results. We have been witnessing a rapid growth in number of tests and patient visits, outpacing the industry. This is evident from the increase in revenue contribution from our retail business which reinforces patient trust and preference for Metropolis. In our endeavor to offer tests that are critical for correct diagnosis, we have added 14 new specialized tests in the area of oncology, genetics and transplant pathology. We will continue to be driven in our pursuit to deliver excellence in pathology while delivering value for all our stakeholders.

Ms Ameera Shah
Managing Director
Metropolis Healthcare Ltd

Key performance highlights (consolidated): H1FY20 vs. H1FY19

Consolidated revenue grew by 15.6% to Rs. 427 Crs as compared to 369 Crs in H1FY19 driven by volume growth through organic expansion.

EBIDTA margins for H1FY20 were 27.58% as compared to 26.30% and EBIDTA for the half year stood at Rs. 118 Crs as compared to 97 Crs in H1FY19, **a growth of 21.3%**

B2C sales increased to 44.4% in H1FY20 as compared to 43.6% in H1FY19, a growth of 80bps

Total patient visit has increased from 4.23 Mn in H1FY19 to 4.92 Mn in H1FY20 registering a **growth of 16.3%** Y-o-Y

Number of tests performed has increased to 9.51 Mn in H1FY20 from 7.91 Mn in H1FY19 registering a **growth of 20.3% Y-o-Y**

We are also pleased to welcome aboard Ms. Ishita Medhekar in the role of CHRO and Mr Rakesh Agarwal as CFO.

Key performance highlights (consolidated): Q2FY20 vs. Q2FY19

Consolidated revenue growth of 15.6% @ 223 Crore backed by robust volume growth

Robust operating performance

Growth in total number of patients: 15.7% | Growth in number of tests performed: 20.1%

Accounting EBIDTA @ INR 63 Crore, 28.0% on revenue (18.8% growth)

Reported PAT @ INR 43 crore, 19.3% on revenue (43.7% growth)

MEDIA RELEASE

GLOBAL ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

AWARDS AND ACCOLADES

Our Company was awarded **Iconic Pathology Lab** Award by Mid-Day Health & Wellness Awards in September 2018

Metropolis received the **'Best Diagnostic Laboratory'** in India award at the Women's Health Conference 2019 supported by the Ministry of AYUSH & Ministry of Health & Family Welfare.

Our Company was awarded special jury mention for **"Service Excellence (Diagnostic Centre)"** by FICCI at the Healthcare Excellence Awards 2018

Our Company was awarded for **"Excellence in Customer Service & Delivery"** by Biotrains, 2018

Metropolis Healthcare won the **Best Temperature Controlled Project of the year** at the Cold Chain Summit Awards held in Mumbai, 2018

Metropolis Healthcare honored for **Excellence in Customer Service & Delivery** at the Home Healthcare Summit & Awards

Recent Accolades

Metropolis wins the Healthcare Leadership Awards, 2019 at Uttar Pradesh Healthcare Leadership Awards 2019 held at Lucknow. Chief Guest Shri Brajesh Pathak, Cabinet Minister of Legislative conferred the award to Metropolis

Metropolis Healthcare Ltd won the award for Best IT Practices at the Data Center Summit, – October 2019

RV Metropolis was awarded by the Karnataka Government for reporting the highest number of TB Cases amongst private laboratories in the state – September 2019

Metropolis Healthcare was recently bestowed with Best IT Enabled Pathology Chain award during the 4th Digital Innovation Health Summit and CIO Awards at Kolkata. September 2019

Our Managing Director, Ms Ameera Shah was listed amongst the Most Powerful Women in Business by Fortune India 2019 and Business Today 2019 – October 2019

Our Founder and Chairman, Dr. Sushil Shah was honored as the Iconic Personality in Healthcare by Mid-Day at the Mid-Day Healthcare and Wellness Awards September 2019

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade; which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

| Company | Investor Relations Advisors: |
|---|---|
|  <p>Metropolis Healthcare Limited CIN - U73100MH2000PLC192798</p> |  <p>Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285</p> |
| <p>Ms. Nadhiya Mali – Corporate Communications corpcomm@metropolisindia.com investor.relations@metropolisindia.com www.metropolisindia.com</p> | <p>Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net / sagar.shroff@sgapl.net +91-77383 77756 / +91-9820519303 www.sgapl.net</p> |